Parkinson's Insights

No Silver Bullet 4PD

"The Biological Clock: When Parkinson's Meets the Aging Brain" by Dr L Shih

In this insightful session, we were joined by Dr Ludy Shih, Associate Professor of Neurology at Harvard Medical School and Clinical Director at Beth Israel Deaconess Medical Center. Dr Shih explored the complex relationship between the natural process of brain aging and the specific pathology of Parkinson’s disease. Key Takeaways The Aging Intersection: Dr Shih discussed how Parkinson's does not exist in a vacuum; it interacts with the "biological clock" of the brain. She highlighted that many of the cellular and molecular mechanisms we see in Parkinson’s—such as mitochondrial dysfunction and oxidative stress—are also fundamental components of the normal aging process. A System-Wide Approach: A major focus of the talk was that aging is not limited to the brain. Dr Shih explained how "non-neurologic" systems (such as the cardiovascular and metabolic systems) undergo their own aging processes, which can significantly impact the progression and symptom management of those living with Parkinson's. The Power of Longitudinal Data: Drawing from her extensive work with the Framingham Heart Study, Dr Shih shared how tracking health data across generations helps researchers distinguish between "normal" aging and the specific neurodegenerative changes associated with Parkinson’s. Resilience and Reserve: The session emphasized the importance of building "cognitive and motor reserve." By understanding how the brain ages, we can better implement lifestyle strategies—such as targeted exercise and social engagement—to enhance the brain's resilience against disease progression. Why This Matters for our Community Understanding the overlap between aging and Parkinson's helps us move away from a "one-size-fits-all" approach. It highlights that maintaining overall systemic health (heart health, metabolic health, and mental wellness) is just as vital as managing dopamine levels. By slowing the "biological clock" through proactive lifestyle choices, we can positively influence the trajectory of the condition.

Protein, Levodopa & Metabolic Management

Protein, Levodopa & Metabolic Management

Food As Medicine for Parkinson’s Series Part 5: Protein, Levodopa & Metabolic Management As we move into the fifth part of our "Food is Medicine" series, we shift our focus to one of the most critical daily challenges for people with Parkinson’s Disease: the relationship between dietary protein and medication effectiveness. This session is designed to be the perfect next step for those who have mastered the basics and are ready for an advanced, highly specific look at metabolic management. Protein is essential not only for anabolic health but for the production of dopamine itself. But for those taking Levodopa, it can be a double-edged sword. Because specific amino acids in protein use the same transport carrier as your L-dopa medication, the timing of taking specific protein food in relation to L-dopa, needs to be precise. This webinar provides a specific and practical roadmap for timing protein intake relative to the time of taking L-dopa. The results will demonstrate how specialised individualised monitoring of drug response can manage the dreaded “off” periods and enable best efficacy of L-dopa. The presentation will also highlight the different metabolic processes that need to be supported in Parkinson’s Disease as well as Multidisciplinary Management. About the Speaker: Lucille Leader (www.lucilleleader.com) Lucille Leader is a renowned figure in the field of Nutritional Therapy specifically tailored for Parkinson’s Disease. Based in London, she has spent decades bridging the gap between clinical neurology and nutritional science. She is a Nutrition Director of the Parkinson’s Disease Integrated Nutrition Clinic and has authored and co-authored several definitive texts in peer reviewed Journals, including Movement Disorders and six Books on Parkinson’s Disease, including leading Neurologists and Parkinson’s Disease Health Care Specialists. Her work has earned her the “Quality of Life in Parkinson’s Disease Award” from the United States of America, the “Outstanding Practice Award” and the “Highly Commended Outstanding Practice Award” in the UK. She has been a Member of the Forum for Food and Health of the Royal Society of Medicine in London UK and Lecturer on Academic MSc Degree Courses in Parkinson’s Disease, Multiple Sclerosis and Medical Collaboration for Nutritional Therapists. She has lectured at International Parkinson’s Disease Congresses. Lucille is celebrated for her "bench-to-bedside" approach, taking complex metabolic processes and turning them into manageable, daily protocols. Her work focuses on the biochemical support of pathways that support dopamine production and other biochemical needs which contribute to functional health in Parkinson’s Disease. Her mission, with that of her Clinic Medical Director Dr Geoffrey Leader, is to enable people with Parkinson’s and their Supporters / Carers to become empowered with as much knowledge as possible of Parkinson’s Drugs, Nutrients, Drug - Nutrient Interactions, Support of Essential Biochemical Needs, Intestinal Function and Management of Cellular Energy, amongst other aspects. Active empowerment produces a feeling of well-being for both people with Parkinson’s and their Supporters, She is also aware that Parkinson’s has multi-factorial implications and therefore recommends a multidisciplinary team approach, working always in collaboration with patients’ GPs and specialists for referrals to the appropriate healthcare professionals. Lucille is celebrated for her "bench-to-bedside" approach, taking complex metabolic processes and turning them into manageable, daily protocols. Clinical Nutrition is Applied Biochemistry and her work therefore focuses on metabolic support that serves optimum cellular function within the confines of Parkinson’s Disease.

Advanced Nutraceuticals for Brain Health and Mitochondrial Support

Advanced Nutraceuticals for Brain Health and Mitochondrial Support

Food as Medicine for Parkinson's Part 6: Advanced Nutraceuticals for Brain Health and Mitochondrial Support The sixth instalment of the Food as Medicine series moves beyond the kitchen to the cutting-edge of clinical supplementation. This session provides an objective look at how specific compounds can support mitochondrial function and protect the brain at a cellular level. We move past the marketing hype to examine what the latest research actually says about the supplements currently making waves in the community. Mitochondria are the powerhouses of our cells, and supporting their efficiency is a primary focus for neuroprotection. We will explore the role of NAD+ precursors and the emerging interest in low-dose lithium as potential tools for maintaining cellular energy. The discussion continues with N-Acetylcysteine, a powerful antioxidant that shows promise in supporting brain connectivity, alongside popular natural options like Lion’s Mane for maintaining cognitive clarity. The session also addresses the broader landscape of supplements, from the role of Green Tea in managing protein health to an evidence-based review of CBD for those seeking better sleep and lower anxiety. By merging rigorous scientific data with real-world clinical observations, we aim to provide a clear roadmap through the complex world of nutraceuticals, helping you identify which options offer the most genuine potential for long-term health. About the speaker: We are honoured to be joined by Dr Tanya Denne, a distinguished Naturopathic Doctor and researcher. Dr Denne is a leading advocate for "Personalised Medicine," a philosophy that treats the whole person rather than just a set of symptoms. Her evidence-based approach views nutrition as a foundational pillar of care, bridging the gap between traditional neurology and complementary disciplines. With her extensive research background, including her work on Mucuna pruriens, Dr Denne empowers people to move from being passive recipients of care to proactive partners in their own health journey.

Michel Planquart

Michel Planquart

Diagnosed in 2020, Michel manages his condition with the dedicated rigour of an athlete. Through his holistic routine and practical tools, he empowers others to actively influence their own progression.

Newsletter

Subscribe to receive regular emails with the latest news, webinars, Bas Bloem podcasts, and Michael Okun posts.

Frequency
Prof. Bas Bloem

Prof. Bas Bloem

Radboud University

A world-leading neurologist and pioneer of patient-centred care, specialising in lifestyle and exercise interventions for Parkinson's.

EP 29 - The Parkinson Weekly Helpdesk

EP 29 - The Parkinson Weekly Helpdesk

🎙️ We’re back with the twenty-ninth episode of Parkinson Weekly, hosted by Prof. Bas Bloem — and the second instalment of the Parkinson Weekly Helpdesk.In this episode, Prof. Bloem answers three new listener questions covering some of the most talked-about topics in Parkinson’s care.He explores the role of diet and the gut, offering practical advice on nutrition, constipation, and how these may impact medication effectiveness. The episode also dives into Mucuna pruriens — what it is, how it compares to standard levodopa therapy, and when it may (or may not) be appropriate.Finally, Prof. Bloem discusses cognitive training, addressing whether brain exercises can help manage symptoms or slow cognitive decline.As always, the Helpdesk combines evidence with real-world clinical insight — helping to cut through conflicting advice and focus on what truly matters for patients.Have a question you’d like Bas to answer in a future episode? Email us at parkinsonweekly@gmail.com – we’d love to hear from you.

PodcastVideo
EP 28 - The Parkinson Weekly Helpdesk

EP 28 - The Parkinson Weekly Helpdesk

🎙️ We’re back with the twenty-eighth episode of Parkinson Weekly, hosted by Bas Bloem.In Episode 28, we introduce a brand-new segment — the Parkinson Weekly Helpdesk — where Prof. Bloem answers listener-submitted questions from across the global Parkinson’s community. Following an overwhelming response, this new format tackles three key questions per episode, offering practical, evidence-based insights while ensuring advice remains general and applicable to all.This first Helpdesk episode explores:The growing interest in methylene blue and whether there is any real clinical evidence behind its use in Parkinson’s diseaseHow to regain confidence after a fall, including the role of balance confidence training and physiotherapyThe broader topic of supplements in Parkinson’s, examining what the evidence actually shows — and where caution is neededProf. Bloem brings his characteristic clarity and scientific rigour to each topic, highlighting the importance of distinguishing promising theory from proven, evidence-based treatments, while also addressing the real concerns and experiences of people living with Parkinson’s.A thoughtful and highly practical episode that marks the start of an important new initiative — designed to answer your questions, at scale.Have a question you’d like Bas to answer in a future episode? Email us at parkinsonweekly@gmail.com – we’d love to hear from you.

PodcastVideo
Prof. Michael Okun

Prof. Michael Okun

University of Florida

A renowned neuroscientist and medical director of the Parkinson's Foundation, widely regarded as a global authority on advanced Parkinson's therapies.

Artificial intelligence has arrived in Parkinson’s disease diagnosis, and many physicians and persons with Parkinson’s are asking the same questions. Can a computer really recognize Parkinson’s disease better than a neurologist? Will AI replace doctors? Can we trust algorithms trained on thousands of MRI scans and wearable sensor recordings? What happens when the AI gets it wrong? These are not science fiction questions anymore. They are unfolding now in clinics and research centers across the world. The excitement is real, however so is the controversy. Parkinson’s disease remains a clinical diagnosis, and no computer currently replaces the expertise of a skilled movement disorders neurologist. Yet for the first time in history, AI tools are beginning to detect patterns invisible to the human eye, and they may fundamentally reshape how we diagnose and understand Parkinson’s disease in the coming decade.
https://michaelokun.substack.com/p/how-artificial-intelligence-will #ai #parkinson

Artificial intelligence has arrived in Parkinson’s disease diagnosis, and many physicians and persons with Parkinson’s are asking the same questions. Can a computer really recognize Parkinson’s disease better than a neurologist? Will AI replace doctors? Can we trust algorithms trained on thousands of MRI scans and wearable sensor recordings? What happens when the AI gets it wrong? These are not science fiction questions anymore. They are unfolding now in clinics and research centers across the world. The excitement is real, however so is the controversy. Parkinson’s disease remains a clinical diagnosis, and no computer currently replaces the expertise of a skilled movement disorders neurologist. Yet for the first time in history, AI tools are beginning to detect patterns invisible to the human eye, and they may fundamentally reshape how we diagnose and understand Parkinson’s disease in the coming decade. https://michaelokun.substack.com/p/how-artificial-intelligence-will #ai #parkinson

PostOpen details
Could AI help uncover hidden Parkinson’s subtypes years earlier? Multimodal means combining many different types of information such as genetics, brain scans, spinal fluid markers and cognitive testing into one analysis. Reyes and colleagues describe in a new paper in npj Artificial Intelligence how a new AI framework called SPARROW may help identify Parkinson’s disease subtypes using multimodal reasoning and interpretable AI.
Key points:
-	SPARROW combined genetics, MRI brain scans, spinal fluid biomarkers and cognitive testing into a single reasoning framework for Parkinson’s disease subtyping.
-	The AI system achieved strong accuracy in distinguishing slow, moderate and fast progressing Parkinson’s disease subtypes using baseline patient data.
-	The system generated step by step reasoning traces, allowing health care providers to better understand how the AI arrived at each subtype decision.
My take: Parkinson’s disease is not one disease. It is many diseases hiding under one name. This study is exciting because it moves beyond simply identifying Parkinson’s and instead asks whether AI can help us understand who may progress faster and why. The interpretability piece is critical. Black box AI will struggle in neurology clinics. Transparent reasoning may be the bridge that builds trust and utility. The performance of this approach may not be as good as a clinician. Also, the scientists turned the imaging data into text.
Here are 5 points that resonated w/ me:
1- Parkinson’s disease likely contains multiple biological subtypes and these differences may explain why symptoms and progression vary so widely between folks.
2- Cognitive testing still emerged as one of the strongest signals in predicting subtype and progression.
3- MRI and genetic information alone were weak predictors, however when combined w/ other data they improved accuracy substantially.
4- The AI system was designed to tolerate missing data, which mirrors real world neurology practice where every test is not always available.
5- The future of Parkinson’s care may involve AI systems that help health care providers personalize prognosis, treatment selection and monitoring much earlier #ai

Could AI help uncover hidden Parkinson’s subtypes years earlier? Multimodal means combining many different types of information such as genetics, brain scans, spinal fluid markers and cognitive testing into one analysis. Reyes and colleagues describe in a new paper in npj Artificial Intelligence how a new AI framework called SPARROW may help identify Parkinson’s disease subtypes using multimodal reasoning and interpretable AI. Key points: - SPARROW combined genetics, MRI brain scans, spinal fluid biomarkers and cognitive testing into a single reasoning framework for Parkinson’s disease subtyping. - The AI system achieved strong accuracy in distinguishing slow, moderate and fast progressing Parkinson’s disease subtypes using baseline patient data. - The system generated step by step reasoning traces, allowing health care providers to better understand how the AI arrived at each subtype decision. My take: Parkinson’s disease is not one disease. It is many diseases hiding under one name. This study is exciting because it moves beyond simply identifying Parkinson’s and instead asks whether AI can help us understand who may progress faster and why. The interpretability piece is critical. Black box AI will struggle in neurology clinics. Transparent reasoning may be the bridge that builds trust and utility. The performance of this approach may not be as good as a clinician. Also, the scientists turned the imaging data into text. Here are 5 points that resonated w/ me: 1- Parkinson’s disease likely contains multiple biological subtypes and these differences may explain why symptoms and progression vary so widely between folks. 2- Cognitive testing still emerged as one of the strongest signals in predicting subtype and progression. 3- MRI and genetic information alone were weak predictors, however when combined w/ other data they improved accuracy substantially. 4- The AI system was designed to tolerate missing data, which mirrors real world neurology practice where every test is not always available. 5- The future of Parkinson’s care may involve AI systems that help health care providers personalize prognosis, treatment selection and monitoring much earlier #ai

PostOpen details

Recommended Activities